Long-term consequence of elevated thyroglobulin in differentiated thyroid cancer.

@article{Yim2013LongtermCO,
  title={Long-term consequence of elevated thyroglobulin in differentiated thyroid cancer.},
  author={Ji Hye Yim and Eui Young Kim and Won Bae Kim and Won Gu Kim and Tae Yong Kim and Jin-Sook Ryu and Gyungyub Gong and Suck Joon Hong and Jong Ho Yoon and Young Kee Shong},
  journal={Thyroid : official journal of the American Thyroid Association},
  year={2013},
  volume={23 1},
  pages={
          58-63
        }
}
  • J. Yim, Eui Young Kim, +7 authors Y. Shong
  • Published 4 January 2013
  • Medicine
  • Thyroid : official journal of the American Thyroid Association
BACKGROUND Serum thyroglobulin (Tg) is the most sensitive biomarker for recurrence of differentiated thyroid cancer (DTC). We have assessed the changing pattern of stimulated Tg (sTg) and the clinical course of patients with no structural evidence of disease (NSED), based on imaging studies such as neck ultrasonography (US), fluorodeoxyglucose positron emission tomography, and/or chest computed tomogram (CT). We sought to determine if, in patients with DTC who had been treated with bilateral… 
Value of the Postablative Thyroglobulin Measurements for Assessment of Disease-Free Status in Patients with Differentiated Thyroid Cancer
Aim: The aim of the study is to evaluate the value of thyroid-stimulating hormone (TSH)-stimulated thyroglobulin (sTg) measurements by the end of the 1st-year postablation in differentiated thyroid
Outcome of Patients With Differentiated Thyroid Cancer Treated With 131-Iodine on the Basis of a Detectable Serum Thyroglobulin Level After Initial Treatment
TLDR
There is a beneficial effect of 131I therapy on outcome of patients with DTC treated on the basis of elevated Tg value, and survival is affected by achievement of CR or PR at 12 months evaluation after 131I Therapy and by the presence of distant metastases at WBS.
Surveillance of patients with differentiated thyroid cancer and indeterminate response: a longitudinal study on basal thyroglobulin trend
TLDR
It is found that, in DTC patients with indeterminate response, rising values of unstimulated Tg, independently from the basal levels, may be useful to identify patients with progressive disease.
Papillary thyroid carcinomas with biochemical incomplete or indeterminate responses to initial treatment: repeat stimulated thyroglobulin assay to identify disease-free patients
TLDR
In unselected PTC cohorts with incomplete/indeterminate biochemical responses to thyroidectomy and RRA, periodic remeasurement of stimulated Tg allows most patients to be classified as disease-free.
Identification of Intermediate- to High-Risk Papillary Thyroid Carcinoma Patients Who May Be Safely Managed without the Performance of Delayed Stimulated Thyroglobulin Measurements following Total Thyroidectomy and Radioactive Iodine Therapy
TLDR
Based on pre- and postoperative parameters, a substantial proportion of patients with PTCs in the intermediate- and high-risk classes could avoid aggressive follow-up measures.
Time trends of thyroglobulin antibody in ablated papillary thyroid carcinoma patients: Can we predict the rate of negative conversion?
TLDR
It is clearly showed that abl-TgAb titers and abl-TPOAb status can predict the rate of negative conversion, which can guide the optimal timing for additional examination in patients positive for TgAb during follow-up.
Superiority of delayed risk stratification in differentiated thyroid cancer after total thyroidectomy and radioactive iodine ablation
TLDR
DRS is superior to ATA risk stratification in predicting structural disease progression for DTC patients and there was no significant difference in deviances between the uses of DRS alone and the use of both DRS and ATArisk stratification.
Analysis of BRAFV600E Mutation and Persistence of Papillary Thyroid Cancer after Total Thyroidectomy and Routine Central Neck Dissection
TLDR
BRAF V600E mutation is not an independent predictive factor for the persistence of papillary thyroid cancer (PTC) after TT and routine CND.
UNFAVORABLE RESPONSES TO RADIOIODINE THERAPY IN N1B PAPILLARY THYROID CANCER: A PROPENSITY SCORE MATCHING STUDY.
  • Yanqing Liu, H. Li, Jierui Liu, Yansong Lin
  • Medicine
    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • 2019
TLDR
N1b PTC patients showed inferior responses to surgery and RAI therapy compared to N1a patients, and N1b was confirmed to be an independent factor predicting unfavorable responses to RAi therapy.
Contemporary debates in adult papillary thyroid cancer management.
TLDR
This review discusses controversial issues in adult papillary thyroid cancer management at both ends of the disease spectrum and provides additional evidence that will decrease morbidity in low-risk patients and improve outcomes in those with distant metastatic disease.
...
1
2
3
...

References

SHOWING 1-10 OF 12 REFERENCES
Thyroid cancer recurrence in patients clinically free of disease with undetectable or very low serum thyroglobulin values.
  • R. Kloos
  • Medicine
    The Journal of clinical endocrinology and metabolism
  • 2010
TLDR
The prevalence of postablation thyroid cancer recurrence is predicted by the rhTSH-Tg response with an optimal Tg threshold of 2.5 ng/ml or greater, which is more accurately predicted tumor recurrence than basal Tg.
Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients.
TLDR
The present data confirm that in this selected cohort of patients, 74-185 MBq (131)I-total body scan (TBS) has no clinical interest in the initial work-up and during the subsequent follow-up because it was negative in all patients, except in one with recurrent disease.
Management of differentiated thyroid cancer with rising thyroglobulin and negative diagnostic radioiodine whole body scan.
  • M. Chao
  • Medicine
    Clinical oncology (Royal College of Radiologists (Great Britain))
  • 2010
TLDR
A decrease in serum Tg in 62% of patients with DTC with elevated Tg and negative scan results suggests that (131)I therapy has a therapeutic effect for more than one-half of patients when the Tg level is considered an index of tumour burden.
A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma.
TLDR
A surveillance guideline is proposed using TSH-stimulated Tg levels for patients who have undergone total or near-total thyroidectomy and (131)I ablation for DTC and have no clinical evidence of residual tumor with a serum Tg below 1 micro g/liter during THST.
Empiric high-dose 131-iodine therapy lacks efficacy for treated papillary thyroid cancer patients with detectable serum thyroglobulin, but negative cervical sonography and 18F-fluorodeoxyglucose positron emission tomography scan.
  • W. Kim, J. Ryu, +8 authors Y. Shong
  • Medicine
    The Journal of clinical endocrinology and metabolism
  • 2010
TLDR
Empirical RAI therapy and posttreatment WBS were not useful diagnostically or therapeutically in patients with positive serum stimulated Tg if such patients had negative USG and negative FDG-PET findings after initial treatment of PTC.
Detection of residual and recurrent differentiated thyroid carcinoma by serum thyroglobulin measurement.
TLDR
Serum Tg measurements should be interpreted relative to the TSH status of the patient, and the optimal degree of TSH suppression for a patient should be based on clinical judgment, relative to tumor staging and the risks from iatrogenic hyperthyroidism.
Management of recurrent/persistent papillary thyroid carcinoma: efficacy of the surgical option.
  • K. Schuff
  • Medicine
    The Journal of clinical endocrinology and metabolism
  • 2011
TLDR
Three recent studies suggest that surgical intervention for locoregional recurrence can indeed achieve biochemical remission (undetectable TSH-stimulated serum thyroglobulin), and contribute additional information to be considered in the assessment of the efficacy of lymph node dissection for locOREgional disease.
Serum Basal thyroglobulin measured by a second-generation assay correlates with the recombinant human thyrotropin-stimulated thyroglobulin response in patients treated for differentiated thyroid cancer.
TLDR
Recombinant human thyrotropin (rhTSH) stimulation is frequently used to assess the disease status of patients treated for differentiated thyroid cancer (DTC) when basal (unstimulated) thyroglobulin (b-Tg) is below the assay sensitivity limit, and correlations between four different assays showed that the use of a fixed Tg cut-off was influenced by assay selection.
Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.
TLDR
Evidence-based recommendations in response to the appointment as an independent task force by the American Thyroid Association to assist in the clinical management of patients with thyroid nodules and differentiated thyroid cancer represent, in the authors' opinion, contemporary optimal care for patients with these disorders.
Effects of therapeutic doses of 131I in thyroid papillary carcinoma patients with elevated thyroglobulin level and negative 131I whole‐body scan: comparative study
TLDR
The effect of therapeutic doses of 131I in patients with elevated thyroglobulin level but negative DxWBS is evaluated.
...
1
2
...